Similar articles

• Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin.

  Fiorelli EM, Rossi RE; GrAM (Gruppo di Autoformazione Metodologica). Fiorelli EM, et al. Intern Emerg Med. 2018 Oct;13(7):1089-1091. doi: 10.1007/s11739-018-1886-y. Epub 2018 Jun 12. Intern Emerg Med. 2018. PMID: 29948831 No abstract available.
• Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.

  Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, Büller HR; Hokusai-VTE investigators. Raskob GE, et al. Lancet Haematol. 2016 Aug;3(8):e379-87. doi: 10.1016/S2352-3026(16)30057-6. Epub 2016 Jul 1. Lancet Haematol. 2016. PMID: 27476789 Clinical Trial.
• Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer.

  Pritchard ER, Murillo JR Jr, Putney D, Hobaugh EC. Pritchard ER, et al. J Oncol Pharm Pract. 2019 Jan;25(1):52-59. doi: 10.1177/1078155217726158. Epub 2017 Aug 21. J Oncol Pharm Pract. 2019. PMID: 28825375
• Cancer-associated thrombosis: investigating the role of new oral anticoagulants.

  Franchini M, Bonfanti C, Lippi G. Franchini M, et al. Thromb Res. 2015 May;135(5):777-81. doi: 10.1016/j.thromres.2015.02.024. Epub 2015 Feb 26. Thromb Res. 2015. PMID: 25743884 Review.
• Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer.

  Walenga JM, Lyman GH. Walenga JM, et al. Crit Rev Oncol Hematol. 2013 Oct;88(1):1-18. doi: 10.1016/j.critrevonc.2013.06.007. Epub 2013 Jul 12. Crit Rev Oncol Hematol. 2013. PMID: 23849978 Review.